XML 28 R15.htm IDEA: XBRL DOCUMENT
v3.26.1

Accounts Payable and Accrued Liabilities | 6 Months Ended
--- | ---
Jun. 30, 2026
Payables and Accruals [Abstract] |
Accounts Payable and Accrued Liabilities | 8. Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consist of the following (in thousands):
| As of
| June 30, 2026 |  | December 31, 2025
Accounts payable and other accrued operating expenses | $ | 74,555 |  |  | $ | 79,907 |
Accrued clinical trial expenses | 34,443 |  |  | 34,329 |
Accrued professional fees | 25,014 |  |  | 23,658 |
Accrued technical operation expenses | 21,730 |  |  | 22,533 |
Accrued compensation and employee related costs | 61,579 |  |  | 111,514 |
Accrued royalty and milestones payable | 37,774 |  |  | 17,101 |
Revenue Interest Payments payable | 7,553 |  |  | 6,449 |
Accrued sales allowances and related costs | 146,373 |  |  | 70,869 |
Accrued French rebate payable | 9,062 |  |  | 6,960 |
Contingent consideration | — |  |  | 57,799 |
Accrued milestone payment to AstraZeneca | — |  |  | 15,000 |
Other accrued liabilities | 10,846 |  |  | 9,941 |
| $ | 428,929 |  |  | $ | 456,060 |

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration